Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced topline efficacy results from a double-masked, randomized, placebo-controlled study (AR-13324-CS206; NCT03233308) designed to evaluate the effect of Rhopressa® (netarsudil ophthalmi